Home Latest Articles
Latest Articles
  • Lu LI, Junfei ZHOU, Chang YUAN, Yunqi LV
    World Clinical Drug. 2023, 44(7): 751-756.
    Objectives

    To investigate the influence of age and gender on the median effective dose of remimazolam for painless gastroscopy.

    Methods

    Patients who underwent painless gastroscopy were divided into 6 groups according to age and gender, group A: young women (18~44 years old), group B: middle-aged women (45~59 years old), group C: elderly women (60~75 years old), group D: young men (18~44 years old), group E: middle-aged men (45~59 years old), and group F: elderly men (60~75 years old). Patients were administrated with 10 μg/kg alfentanil and different dose of remimazolam, and 0.20 mg/kg was set as the initial dose. The dose of remimazolam of the next patient was determined by the Dixon’ up-down modified sequential method. The sedative effect of different doses of remimazolam and the occurrence of adverse reactions in each group were recorded. Probabilistic regression analysis was used to analyze the median effective dose (ED50), 95% confidence interval (CI) and dose-response relationship of remimazolam in each group.

    Results

    A total of 167 patients were finally enrolled, including 26 cases in group A, 25 cases in group B, 27 cases in group C, 28 cases in group D, 33 cases in group E and 28 cases in group F. The ED50 of remimazolam in group A (0.33 mg/kg, 95%CI: 0.26~0.37 mg/kg) was higher than that in group C~group F, and the differences were statistically significant (P<0.05). The ED50 of group B (0.32 mg/kg, 95%CI: 0.24~0.36 mg/kg) was higher than that in group C, E and F, and the differences were statistically significant. There was no statistically difference in ED50 and adverse reactions among the other groups.

    Conclusion

    ED50 of remimazolam combined with alfentanil used for painless gastroscopy in young and middle-aged females was higher than that in same age males and elderly women.

  • Dujuan QIAO, Linong YAO
    World Clinical Drug. 2023, 44(7): 757-761.

    Esketamine, a dextral isomers of ketamine, is an anesthetic drug with analgesia, amnesia and loss of consciousness. It also has hemodynamic stability, less respiratory inhibition, anti-inflammatory and neuroprotective effects. It is one of the priority drugs for analgesic and sedative treatment of critically ill patients in intensive care units (ICU). This article reviewed the pharmacological effects of esketamine and its clinical application in ICU.

  • Ting LIU, Siyuan LI
    World Clinical Drug. 2023, 44(7): 762-766.

    Etomidate is widely used in clinical anesthesia management because of its good cardiovascular stability. However, it has a transient inhibitory effect on adrenocortical function. Dexamethasone is a widely used glucocorticoid during perioperative period, which can obviously inhibit the function of hypothalamic pituitary adrenal cortical axis. In clinical practice, the combination of these two drugs is very common. This article reviewed the effects of these two drugs on adrenal cortisol secretion.

  • Mingjie ZHANG, Zhao DONG, Shengyuan YU
    World Clinical Drug. 2023, 44(6): 525-526.
  • Xiaoyan SONG, Xiaoping WANG
    World Clinical Drug. 2023, 44(6): 527-530.

    Migraine is a common and chronic disease that is characterized by episodic headache that can cause disability, accompanied by aura and other symptoms. The etiology is relatively unknown, and four rare related genes have been identified. The pathogenesis of migraine may be related to spreading depolarization, which probably causes aura and initiates activation of trigeminal pain pathway, ultimately triggering headache. Vasodilation is possibly a secondary phenomenon. The treatment of migraine varies according to the severity of the attack. Calcitonin gene related peptide (CGRP) receptor antagonists and selective 5-hydroxytryptamine 1F receptor agonist are expected to be effective in acute phase. Monoclonal antibodies targeting CGRP pathways and receptor antagonists are expected to prevent migraine because of their good efficacy and tolerance. Intramuscular injection of botulinum toxin A can be a treatment option for chronic migraine. The emergence of new medications indicates the bright future for migraine management.

  • Tengyu MA, Guange YANG
    World Clinical Drug. 2023, 44(6): 531-535.

    Migraine is a common neurological disease, and its pathogenesis has not been clearly defined. It is believed that migraine as a complex hereditary disease is caused by the combination of genetic factors and environmental factors. At present, the genetic research of migraine has only obtained a unified understanding in several single gene inherited migraine. In recent years, the whole genome association analysis technique has been applied to the genetic research of migraine and a lot of achievements have been obtained. Migraine candidate genes have also been replicated in some studies. This article reviewed the research progress in genetic of migraine, in order to provide reference for further improving the diagnosis and treatment strategies of migraine.

  • Shan JIANG, Mei JIANG, Xiaofei YU
    World Clinical Drug. 2023, 44(6): 536-541.

    Headache is a common neurological disorder. Among them, primary headache is more common, and seriously affects the quality of life of patients. This article tracked the progress on western medicine treatment of primary headache, combined the unique understanding of traditional Chinese medicine (TCM) on the diagnosis and treatment of headache, expounded the clinical advantages of TCM and western medicine in the treatment of headache, and looked forward to the development prospects of integrative TCM and western medicine in the treatment of headache.

  • Jialin WANG, Yiqin GE
    World Clinical Drug. 2023, 44(6): 542-546.

    Primary trigeminal neuralgia (PTN) is one of the common causes of head and facial pain in clinical practice. The etiology and pathogenesis of PTN have not been clearly defined. Although there are many treatment methods for PTN, but there is a lack of durable and effective treatment. Drug therapy is the first option of PTN, but the long-term efficacy is poor. For the patients who fail to respond to drug therapy or can not tolerate the side effects of drugs, surgery is another option, including microvascular decompression, partial trigeminal rhizotomy, percutaneous rhizotomy on the Gasserian ganglion, peripheral branch surgery of the trigeminal nerve, and electrical nerve stimulation. For patients who fail to respond to medical treatment and can not tolerate surgery, stereotactic radiosurgery can also be selected, for example, gamma knife and cyberknife. This article reviewed the treatment progress on PTN, in order to provide clinical reference for clinical practice.

  • Hua TIAN, Xiaoli LI, Jinye WANG, Jing HUANG
    World Clinical Drug. 2023, 44(6): 547-551.
    Objective

    To evaluate the protective effects and mechanism of mesalazine on ethanol induced gastric ulcer (GU) in rats.

    Methods

    Male SD rats were randomly divided into control group, ulcer group, omeprazole+ulcer group and mesalazine+ulcer group, with 10 rats in each group. GU was caused by oral administration of absolute ethanol (5 ml/kg) in rats. Omeprazole group and mesalazine group took omeprazole (20 mg/kg) or mesalazine (50 mg/kg) orally one hour before taking ethanol, respectively. One hour after ethanol treatment, the ulcer area, histopathology, lipid peroxidation, antioxidant enzymes and phosphorylation of nuclear factor (NF)-κB were observed.

    Results

    Mesalazine pretreatment significantly decreased alcohol-induced GU, hemorrhage, hyperemia, and epithelial cell loss in the gastric mucosa. Mesalazine pretreatment reduced the level of malondialdehyde and increased total glutathione and superoxide dismutase in gastric tissues. In addition, it increased the expression levels of cyclooxygenase-1 and prostaglandin (PG)E2, and decreased the phosphorylation of NF-κB.

    Conclusion

    Mesalazine could effectively inhibit ethanol induced acute gastric injury by preventing oxidative damage, stimulating PGE2 production, and inhibiting NF-κB activation.

  • Huidong LI, Xueyu YANG, Wenfan GUO, Xuejun ZHENG, Jigao LU, Yong YANG
    World Clinical Drug. 2023, 44(6): 552-560.
    Objective

    To investigate the effects of wogonin (Wog) on knee osteoarthritis (KOA) in rats by regulating nuclear factor (NF)-erythroid 2-related factor (Nrf2)/Toll like receptor 4 (TLR4)/NF-κB signaling pathway.

    Methods

    SD rats were randomly divided into normal group, model group, Wog low, medium and high dose (10, 30 and 90 mg/kg) groups, and positive control group (celecoxib, 24 mg/kg), with 10 rats in each group. KOA model was established by gavage of papain for 28 days. The mechanical and cold pain thresholds, pathological changes of cartilage, cell apoptosis, inflammatory factors, oxidative stress and protein expression levels were detected.

    Results

    At postoperative D7, D14, D21, and D28, compared with the model group, the mechanical pain threshold and cold pain threshold of Wog medium and high dose groups and positive control group were significantly increased. Pathological damage of cartilage was significantly improved. Cell apoptosis rate, interleukin (IL)-6, IL-1β, tumor necrosis factor (TNF)-α, malondialdehyde, caspase-3, caspase-9, matrix metalloproteinase (MMP)-1, MMP-13, TLR4 protein level and the ratio of nuclear/total NF-κB p65 protein were significantly decreased. The activities of superoxide dismutase, glutathione peroxidase, Nrf2 and heme oxygenase-1 protein were significantly increased (P<0.01).

    Conclusion

    The mechanism of Wog reducing inflammatory damage in KOA rats may be related to upregulating Nrf2 expression and inhibiting TLR4/NF-κB activation.

News